PVLA — Palvella Therapeutics, Inc. Stock Price, Chart & AI Report

Positive Mar 25, 2026 • 22:25 UTC The Motley Fool • Jonathan Ponciano

Palvella Stock Up 340% as Insider Sells Shares. Here's What the Move Does (And Does Not) Signal

Palvella Therapeutics' COO Kathleen Goin sold 4,302 shares worth ~$508,000 on March 18, 2026, through a pre-planned Rule 10b5-1 trading plan adopted in August. The sale should not raise concerns as it was a structured liquidity event tied to option exercises. The stock has surged 340% over the past year, supported by positive Phase 3 results for its lead candidate QTORIN rapamycin (95% of participants showed improvement), a planned New Drug Application submission in H2 2026, and a recent $230 million equity offering.

PVLA insider sale biotech rare skin diseases Phase 3 results clinical-stage stock surge Rule 10b5-1 plan

Sentiment note

Despite insider selling, the company demonstrates strong fundamentals with positive Phase 3 results meeting primary endpoints (95% improvement rate), upcoming NDA submission in H2 2026, and recent $230 million capital raise providing runway for development. The insider sale is part of a pre-planned liquidity event, not a sign of weakening conviction. The 340% stock gain reflects investor confidence in the company's clinical progress and market opportunity in rare dermatological conditions.

Positive Mar 2, 2026 • 12:30 UTC Benzinga • Globe Newswire

Palvella Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares

Palvella Therapeutics (NASDAQ: PVLA) closed its upsized public offering on February 27, 2026, raising $230.0 million in gross proceeds by selling 1,840,000 shares at $125.00 per share, including the full exercise of underwriters' option for 240,000 additional shares. The company plans to use the net proceeds to support development of its QTORIN rapamycin and QTORIN pitavastatin programs for rare skin diseases and vascular malformations.

PVLA public offering capital raise biopharmaceutical rare diseases clinical-stage QTORIN platform rapamycin

Sentiment note

The company successfully closed an upsized public offering, raising $230 million in gross proceeds, which demonstrates investor confidence and provides substantial capital to advance its clinical pipeline for rare disease treatments. The full exercise of underwriters' option indicates strong demand for the offering.

Positive Feb 26, 2026 • 00:57 UTC GlobeNewswire Inc. • Not Specified

Palvella Therapeutics Announces Pricing of Upsized Public Offering

Palvella Therapeutics priced an upsized public offering of 1.6 million shares at $125 per share, raising $200 million in gross proceeds before underwriting costs. The clinical-stage biopharmaceutical company plans to use the funds to support development of its QTORIN rapamycin and QTORIN pitavastatin programs for rare skin diseases and vascular malformations. The offering is expected to close on February 27, 2026.

PVLA public offering biopharmaceutical rare skin diseases vascular malformations QTORIN platform clinical-stage capital raise

Sentiment note

The company successfully completed an upsized public offering at $125 per share, raising $200 million to fund development of its pipeline programs. The offering demonstrates investor confidence and provides substantial capital for advancing clinical programs including positive Phase 3 results mentioned in the article.

Positive Feb 23, 2026 • 22:00 UTC GlobeNewswire Inc. • Na

Palvella Therapeutics to Host Conference Call to Discuss Topline Results from Phase 3 SELVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) in Microcystic Lymphatic Malformations

Palvella Therapeutics announced it will host a conference call on February 24, 2026, at 8:00am ET to discuss topline results from the Phase 3 SELVA clinical trial of QTORIN 3.9% rapamycin anhydrous gel for treating microcystic lymphatic malformations. The company plans to release results at 6:30am ET prior to the call.

PVLA Phase 3 clinical trial QTORIN rapamycin microcystic lymphatic malformations rare skin diseases vascular malformations FDA approval biopharmaceutical

Sentiment note

The company is advancing a late-stage clinical pipeline with Phase 3 trial results expected, demonstrating progress toward potential FDA approval for treatments addressing unmet medical needs in rare diseases with no current approved therapies. The announcement of topline results from a pivotal Phase 3 trial is typically viewed positively by investors as it represents a significant milestone.

Positive Dec 15, 2025 • 11:00 UTC GlobeNewswire Inc. • Palvella Therapeutics

Palvella Therapeutics Announces Positive Topline Results from Phase 2 TOIVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Cutaneous Venous Malformations, a Serious, Rare Genetic Disease with No FDA-approved Therapies

Palvella Therapeutics reported positive Phase 2 trial results for QTORIN™ rapamycin gel in treating cutaneous venous malformations, with 73% of participants showing improvement and no serious adverse events reported.

PVLA rare genetic disease venous malformations clinical trial topical treatment rapamycin

Sentiment note

Achieved statistically significant results in Phase 2 trial, demonstrated potential for first FDA-approved therapy for cutaneous venous malformations, and plans to pursue Breakthrough Therapy Designation

Positive Nov 5, 2025 • 11:00 UTC GlobeNewswire Inc. • Wes Kaupinen

Palvella Therapeutics Announces New QTORIN™ Product Candidate, QTORIN™ Pitavastatin, for the Treatment of Disseminated Superficial Actinic Porokeratosis (DSAP), a Rare, Chronic, and Pre-Cancerous Genetic Skin Disease with No FDA-Approved Therapies

Palvella Therapeutics introduced a new product candidate, QTORIN™ pitavastatin, targeting disseminated superficial actinic porokeratosis (DSAP), a rare genetic skin disease with no current FDA-approved therapies. The company plans to initiate a Phase 2 clinical trial in the second half of 2026.

PVLA DSAP rare skin disease genetic mutation mevalonate pathway topical treatment

Sentiment note

Company is developing an innovative therapeutic approach for a rare disease with no current treatment options, demonstrating potential for significant medical advancement

Positive Apr 9, 2025 • 08:00 UTC GlobeNewswire Inc. • N/A

Ebenbuild Contributes Cutting-Edge Digital Lung Simulations to Pulmonary Fibrosis Drug Development

Ebenbuild's digital twin technology Twinhale was used in a study published in Nature Communications, demonstrating the potential of inhaled therapeutics for treating idiopathic pulmonary fibrosis (IPF). The simulations revealed how the novel inhaled Anticalin® protein PRS-220 can effectively target diseased lung tissue, paving the way for more efficient therapies for IPF patients.

PVLA Ebenbuild Twinhale idiopathic pulmonary fibrosis PRS-220 Anticalin Pieris Pharmaceuticals Pavella Therapeutics

Sentiment note

Pavella Therapeutics, Inc. (formerly Pieris Pharmaceuticals) developed the novel inhaled Anticalin® protein PRS-220, which was shown to achieve effective penetration and coverage in fibrotic lung tissue through the use of Ebenbuild's digital twin technology.